AAA
Affinity Asset Advisors Portfolio holdings
AUM
$676M
This Quarter Return
+14.73%
1 Year Return
+29.75%
3 Year Return
+452.89%
5 Year Return
–
10 Year Return
–
AUM
$676M
AUM Growth
+$676M
(+5.9%)
Cap. Flow
-$4.11M
Cap. Flow
% of AUM
-0.61%
Top 10 Holdings %
Top 10 Hldgs %
50.78%
Holding
109
New
10
Increased
19
Reduced
24
Closed
14
Top Buys
| 1 |
Insmed
INSM
|
$33.7M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$32M |
| 3 |
Ventyx Biosciences
VTYX
|
$9.71M |
| 4 |
Lexeo Therapeutics
LXEO
|
$8.48M |
| 5 |
Enliven Therapeutics
ELVN
|
$8.02M |
Top Sells
| 1 |
Apogee Therapeutics
APGE
|
$19.9M |
| 2 |
SPDR S&P 500 ETF Trust
SPY
|
$16.8M |
| 3 |
Merus
MRUS
|
$13.3M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$8.5M |
| 5 |
INZY
Inozyme Pharma
INZY
|
$8.47M |
Sector Composition
| 1 | Healthcare | 95.02% |
| 2 | Financials | 0.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VRNA
1
Verona Pharma
VRNA
$9.16B
| $57.7M | 7.88% | 610,000 -5,000 | -0.8% | -$473K |
|
|
2
Insmed
INSM
$28.8B
| $47.8M | 6.53% | 475,000 +335,000 | +239% | +$33.7M |
|
3
Xenon Pharmaceuticals
XENE
$2.98B
| $34.4M | 4.7% | 1,100,000 -228,175 | -17% | -$7.14M |
|
4
Arcellx
ACLX
$3.85B
| $32.6M | 4.45% | 495,000 -35,000 | -7% | -$2.3M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $32M | 4.38% | +250,000 | New | +$32M |
|
6
Nuvalent
NUVL
$5.52B
| $31.7M | 4.32% | 415,000 -45,000 | -10% | -$3.43M |
|
|
7
Apogee Therapeutics
APGE
$2.17B
| $30M | 4.1% | 691,899 -459,300 | -40% | -$19.9M |
|
8
Alkermes
ALKS
$4.78B
| $28.6M | 3.91% | 1,000,000 | – | – |
|
9
Protagonist Therapeutics
PTGX
$3.67B
| $24.3M | 3.32% | 440,000 +40,000 | +10% | +$2.21M |
|
10
Madrigal Pharmaceuticals
MDGL
$9.76B
| $24.2M | 3.31% | 80,000 | – | – |
|
11
Teva Pharmaceuticals
TEVA
$21.1B
| $23.5M | 3.2% | 1,400,000 | – | – |
|
|
12
Lexeo Therapeutics
LXEO
$259M
| $14.4M | 1.97% | 3,589,355 +2,108,474 | +142% | +$8.48M |
|
13
Travere Therapeutics
TVTX
$1.56B
| $14.4M | 1.96% | 970,000 -100,000 | -9% | -$1.48M |
|
14
Establishment Labs
ESTA
$1.2B
| $14.3M | 1.95% | 334,863 +54,863 | +20% | +$2.34M |
|
15
Trevi Therapeutics
TRVI
$883M
| $13.9M | 1.89% | 2,534,058 +1,284,058 | +103% | +$7.02M |
|
16
Wave Life Sciences
WVE
$1.53B
| $13M | 1.78% | 2,000,308 +175,308 | +10% | +$1.14M |
|
17
Vera Therapeutics
VERA
$1.38B
| $12.8M | 1.75% | 545,000 +189,857 | +53% | +$4.47M |
|
18
Mineralys Therapeutics
MLYS
$1.03B
| $12.2M | 1.66% | 900,000 -200,000 | -18% | -$2.71M |
|
|
CNTA
19
Centessa Pharmaceuticals
CNTA
$2.25B
| $11.8M | 1.62% | 900,162 -646,500 | -42% | -$8.5M |
|
20
Nurix Therapeutics
NRIX
$714M
| $11M | 1.51% | 967,620 +156,951 | +19% | +$1.79M |
|
21
Rezolute
RZLT
$619M
| $9.81M | 1.34% | 2,200,000 +500,000 | +29% | +$2.23M |
|
|
22
Ventyx Biosciences
VTYX
$171M
| $9.71M | 1.33% | +4,536,182 | New | +$9.71M |
|
23
Spyre Therapeutics
SYRE
$996M
| $9.08M | 1.24% | 606,678 +125,000 | +26% | +$1.87M |
|
|
24
Enliven Therapeutics
ELVN
$1.2B
| $8.02M | 1.1% | +400,000 | New | +$8.02M |
|
25
ProQR Therapeutics
PRQR
$237M
| $7.14M | 0.98% | 3,499,512 +215,000 | +7% | +$439K |
|